ShareValue scores for BIO: Valuation 47, Quality 57, Growth 25, Health 49.

Bio-Rad Laboratories Inc logo

BIO
NYSE

Bio-Rad Laboratories Inc

$342.43(-1.56%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

5% to 15%
Valuation
47
Fair Value
Price vs Value
Quality
57
Moderate
Business Strength
Growth
25
Weak
Revenue & Earnings
Health
49
Moderate
Financial Stability
Momentum
28
Bearish
Price Trend

Company Details

About

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026